Advertisement
Advertisement
November 16, 2026
TRIUMPH Pivotal Trial Begins for Laplace’s Transcatheter Tricuspid Valve Replacement System
KEY TAKEAWAYS
- The first three patients have been enrolled and treated in the randomized cohort of the TRIUMPH pivotal trial.
- The prospective, multicenter investigational device exemption study is evaluating the Laplace transcatheter tricuspid valve replacement system for tricuspid regurgitation.
- Patients are being randomized 2:1 to the investigational Laplace device or a commercially available TTVR device.
November 16, 2026—Laplace Interventional announced that the first three patients have been enrolled and treated in the randomized cohort of the TRIUMPH trial.
According to the company, TRIUMPH is a prospective, multicenter pivotal investigational device exemption study of the company’s prosthetic transcatheter tricuspid valve replacement (TTVR) to treat tricuspid regurgitation. Patients are being randomized 2:1 against a commercial TTVR device. The Laplace device is currently limited to investigational use only and is not commercially available in the United States or any other country, advised the company.
The patients were treated in procedures led by Gaurav Rana, MD, at Ballad Health in Kingsport, Tennessee, and Kamran Muhammad, MD, at Oklahoma Heart Institute in Tulsa, Oklahoma. The Global Principal Investigators of the TRIUMPH pivotal trial are Charanjit Rihal, MD; Kashish Goel, MD; and Brandon Jones, MD.
Dr. Rihal is an interventional cardiologist at Mayo Clinic in Rochester, Minnesota. Dr. Goel is Director of Transcatheter Valve Interventions at Vanderbilt University Medical Center in Nashville, Tennessee. Dr. Jones is Medical Director of Structural Heart Program at Providence St. Vincent Medical Center in Portland, Oregon.
Advertisement
Advertisement